Lawrence Steinman, MD

In this episode of MEDcast, expert neurologists delve into anti-CD20 disease modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS.

In this episode of MEDcast, expert neurologists delve into anti-CD20 disease-modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS. [LISTEN TIME: 48 minutes]

The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses what Amylyx’s FDA approved therapy means for the patient community and future research that may be performed regarding the dosage of the treatment. [WATCH TIME: 5 minutes]

The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses the biggest takeaway from the FDA approval of Amylyx’s therapy, marketed as Relyvrio, and the availability of the treatment for patients with ALS. [WATCH TIME: 5 minutes]

The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discussed updates in ALS research along with the need in future studies following AMX005’s (Relyvrio; Amylyx Pharmaceuticals) recent FDA approval. [WATCH TIME: 4 minutes]

The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses Amylyx’s therapy that was recently approved by the FDA, and what it means for the ALS community and the global healthcare industry. [WATCH TIME: 5 minutes]

Experts in neurology share their hopes for the future of multiple sclerosis treatment and discuss unmet needs and novel targets.

Amit Bar-Or, MD, FRCPC, and Bridget A. Bagert, MD, share their opinions on how to move investigative treatments for multiple sclerosis off the laboratory bench and into clinical practice.

Doctors in neurology comment on the hidden symptoms of multiple sclerosis and debate whether they should be treatment targets.

Experts in neurology comment on clinical trial design considerations and discuss novel imaging techniques and biomarkers that they consider most important to investigate for multiple sclerosis.

Bridget A. Bagert, MD, leads a discussion on the ideal patient populations for using a potential vaccine for multiple sclerosis, and the panel comments on other factors to consider when administering vaccines.

Amit Bar-Or, MD, FRCPC, discusses the potential impact vaccination against Epstein-Barr virus could play on multiple sclerosis rates, highlighting recent investigations.

Experts in neurology discuss screening and diagnostic considerations for a patient newly diagnosed with multiple sclerosis.

Bridget A. Bagert, MD, and Ahmed Obeidat, MD, PhD, examine the clinical implications of a causal link between Epstein-Barr virus and multiple sclerosis and provide insight on how to discuss this link with patients.

Lawrence Steinman, MD, discusses his recent publication, which demonstrated the causal link between Epstein-Barr virus and multiple sclerosis, highlighting key findings and conclusions.

Ahmed Obeidat, MD, PhD, comments on other viruses that have been linked to the development of multiple sclerosis and discusses how they can be both protective and detrimental.

Amit Bar-Or, MD, FRCPC, and Bridget A. Bagert, MD, share their opinions on the role the Epstein-Barr virus plays in the development of multiple sclerosis, highlighting recent publications examining this link.

Scott Newsome, DO, and Lawrence Steinman, MD, discuss the pathophysiology of the interactions between viruses and the immune system and explore how this can lead to autoimmune diseases.

Lawrence Steinman, MD, provides an overview of the role viruses play in the activation of the immune system, highlighting their role in triggering neuroinflammatory conditions.

Alberto Ascherio, MD, DrPH, and Lawrence Steinman, MD, join NeurologyLive in a conversation about the clinical and research implications of a causative relationship between Epstein-Barr virus and multiple sclerosis.

Discussing this year’s virtual ECTRIMS conference, the Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University provided his opinion on recent developments in the MS field. [WATCH TIME: 3 minutes]

The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University discussed the treatment’s potential in the multiple sclerosis space, where there are other competing drugs with similar safety profiles. [WATCH TIME: 4 minutes]

The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University spoke on the safety and efficacy of ublituximab in treating patients with relapsing forms of multiple sclerosis. [WATCH TIME: 4 minutes]

Key opinion leaders in neurology, Lawrence Steinman, MD and Enrique Alvarez, MD, PhD, reflect on future developments in the management of multiple sclerosis and share key advice for community physicians.

Thought leaders in neurology consider the role of BTK inhibitors such as evobrutinib and review the potential impact on patients with progressive multiple sclerosis.

Experts in the management of multiple sclerosis provide key insights into the use of ublituximab in multiple sclerosis and review results of the ULTIMATE I and II trials from the AAN 2021 Annual Meeting.  

Enrique Alvarez, MD, PhD reviews factors to consider when monitoring response to treatment, and Lawrence Steinman, MD comments on patient- and disease-related factors that may impact therapeutic sequencing.

Two experts in multiple sclerosis share insights on the shared decision-making process when selecting a high efficacy therapy and emphasize the importance of disease characteristics and patient preference.

Key opinion leaders in neurology, Lawrence Steinman, MD and Enrique Alvarez, MD, PhD examine some advantages associated with beginning patients on higher-efficacy therapies for relapsing/remitting multiple sclerosis.

Experts in the management of relapsing/remitting multiple sclerosis provide key insights on the importance of early diagnosis and treatment as well as what factors to consider when selecting therapy.